Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
In another study authors found that ADORA
2024-09-12

In another study, authors found that ADORA1 were present on the intrinsically photosensitive retinal ganglion SM-224 (ipRGCs), and application of adenosine to rat retinas reduced light-evoked spiking of ipRGCs through suppression of a cAMP-mediated pathway (Sodhi and Hartwick, 2014). The ipRGCs are
-
Both subcutaneous s c and
2024-09-12

Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel
-
Even within the context of evidence based interventions for
2024-09-12

Even within the context of evidence-based interventions for tobacco screening, the science is imperfect. For example, patients who screen positive for current smoking should receive cessation counseling and prescribed known effective nicotine replacement therapy based on the Public Health Services G
-
The exact etiology of BPH is not
2024-09-12

The exact etiology of BPH is not completely understood, however this pathology has been associated with elevated CHC synthesis levels of the androgen DHT (10). Thus, a valuable strategy in BHP treatment is the reduction of DHT (10) levels, by inhibiting its biosynthetic production [6], [8]. An impo
-
Physiological total plasma LPA levels are normally less than
2024-09-12

Physiological total plasma LPA levels are normally less than 1μM in healthy subjects. LPA levels have been reported to be increased in malignant effusions or plasma in cancer patients [20]. In addition, increasing ATX activity detected in healthy pregnant women in the third trimester of pregnancy ex
-
Roles of Aurora kinases in directly activating
2024-09-12

Roles of Aurora kinases in directly activating multiple oncogenic pathways and promoting proliferation as well as transformation have also been demonstrated. Aurora-A has been shown to up-regulate telomerase reverse transcriptase mRNA through c-myc [26]. The kinase was also implicated in activating
-
br Introduction Cadmium is a major component of heavy
2024-09-12

Introduction Cadmium is a major component of heavy metal pollution. Phytoremediation is considered to be the more effective method for recovering contaminated soil [[1], [2], [3], [4]] via cadmium absorption, transport, and accumulation. Several cadmium-associated proteins have previously been we
-
Analysis of ASK crystal structures as well
2024-09-12

Analysis of ASK1 crystal structures as well as an investigation of how chir99021 4 might bind were undertaken to understand opportunities for engaging Gln756. To this end a docking model derived from PDB 3VW622 was used to predict the binding mode of amide 4 in the ASK1 active site as shown in Fig.
-
In glucose stimulated pancreatic cells B Raf activity
2024-09-11

In glucose-stimulated pancreatic β-cells, B-Raf activity is increased, while Raf-1 activity is under the detection limit (Duan and Cobb, 2010). Thus, B-Raf is the primary protein kinase involved in the rapid activation of ERK1/2 in glucose-treated pancreatic β-cells. Expression of a dominant-negativ
-
Most human diseases e g cancer diabetes and
2024-09-11

Most human diseases (e.g., cancer, diabetes, and neurodegenerative diseases) are complex and multifactorial. Several investigations in the literature focused on new multi-target drug development, which implies active pharmacophores incorporation in one scaffold (Meunier, 2008, Lazar et al., 2004, Te
-
Since artemisinin shows low solubility and poor oral bioavai
2024-09-11

Since artemisinin shows low solubility and poor oral bioavailability [8], [9], derivatizations of artemisinin were carried out and yielded different semisynthetic antimalarial drugs such as artemether and sodium artesunate. Artemether (decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano [4.3-
-
Recently the FDA approved the first blood based
2024-09-11

Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini
-
Initially DPP DPP and prolyl tripeptidyl
2024-09-11

Initially, DPP4, DPP7, and prolyl tripeptidyl peptidase A (PtpA) were the only exopeptidases identified in P. gingivalis. These share substrates according to their altered specificities, as DPP4 is highly specific for Pro at the penultimate position from the N-terminus (P1 position), though it accep
-
A characteristic of iron present in brain fluids is
2024-09-11

A characteristic of iron present in brain fluids is considerable differences between measured values of ferritin and transferrin and the total iron content value (Table 1). Variation of the latter is compatible with differences in individual metabolisms. However differences between total iron conten
-
Imatinib was first approved for the treatment of Philadelphi
2024-09-11

Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h
16419 records 98/1095 page Previous Next First page 上5页 96979899100 下5页 Last page